Mesenchymal stem cells infected with Mycoplasma arginini secrete complement C3 to regulate immunoglobulin production in b lymphocytes

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Lee, D S ^a   Yi, T G ^a   Lee, H J ^a   Kim, S N ^a   Park, S ^b   Jeon, M S ^a   Song, S U ^a  

^a Inha University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

B cells; Complement C3; Mesenchymal stem cells; Mycoplasma

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; CULTURE MEDIUM; IMMUNOGLOBULIN E;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL CULTURE; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; FAST PROTEIN LIQUID CHROMATOGRAPHY; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; LIQUID CHROMATOGRAPHY; MESENCHYMAL STEM CELL; MOUSE; MYCOPLASMA; MYCOPLASMA ARGININE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; DOWN REGULATION; DRUG EFFECTS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MICROBIOLOGY; PHARMACOLOGY; SECRETION (PROCESS);

ANIMALS; B-LYMPHOCYTES; COMPLEMENT C3; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; IMMUNOGLOBULIN E; IMMUNOGLOBULINS; LIPOPOLYSACCHARIDES; MESENCHYMAL STROMAL CELLS; MICE; MYCOPLASMA;

EID: 84901016617     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.147     Document Type: Article

References (39)

1. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006; 1: 365-369.
2. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006; 18: 586-591.
3. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008; 30: 121-127.
4. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008; 251: 131-136.
5. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5: 485-489.
6. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
7. Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 2012; 35: 213-221.
8. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
9. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087.
10. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
11. Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/ suppressive phenotype. Haematologica 2005; 90: 516-525.
12. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
13. Bochev I, Elmadjian G, Kyurkchiev D, Tzvetanov L, Altankova I, Tivchev P et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Int 2008; 32: 384-393.
14. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-1202.
15. Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93: 1301-1309.
16. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z et al. Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng 2005; 11: 110-119.
17. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112: 4991-4998.
18. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37: 604-615.
19. Che N, Li X, Zhou S, Liu R, Shi D, Lu L et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol 2012; 274: 46-53.
20. Rasmusson I, Le Blanc K, Sundberg B, Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65: 336-343.
21. Traggiai E, Volpi S, Schena F, Gattorno M, Ferlito F, Moretta L et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26: 562-569.
22. Ji YR, Yang ZX, Han ZB, Meng L, Liang L, Feng XM et al. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem 2012; 30: 1526-1537.
23. Citti C, Blanchard A. Mycoplasmas and their host: emerging and re-emerging minimal pathogens. Trends Microbiol 2013; 21: 196-203.
24. Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology 2002; 39: 75-90.
25. Logunov D, Shchebliakov DV, Zubkova OV, Shmarov MM, Rakovskaia IV, Gintsburg LA et al. Lipid-associated membrane lipopeptides of M. arginini activate NF-kB by interacting with TLR2/1, TLR2/6, and TLR2/CD14. Mol Gen Mikrobiol Virusol 2009; 2: 25-28.
26. Zinocker S, Wang MY, Gaustad P, Kvalheim G, Rolstad B, Vaage JT. Mycoplasma contamination revisited: mesenchymal stromal cells harboring Mycoplasma hyorhinis potently inhibit lymphocyte proliferation in vitro. PloS One 2011; 6: e16005.
27. Prayson MJ, Venkatarayappa I, Srivastava M, Northern I, Burdette SD. Deep infection with Mycoplasma Arginini in an open femur fracture secondary to an African lion bite: a case report. Injury Extra 2008; 39: 243-246.
28. Jabara HH, Chaudhuri J, Dutt S, Dedeoqlu F, Weng Y, Murphy MM et al. B-cell receptor cross-linking delays activation-induced cytidine deaminase induction and inhibits classswitch recombination to IgE. J Allergy Clin Immunol 2008; 121: 191-196.
29. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9: 43-56.
30. Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol 2005; 17: 237-243.
31. Kremlitzka M, Polgar A, Fulop L, Kiss E, Poor G, Erdei A. Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. Int Immunol 2013; 25: 25-33.
32. Carroll MC. CD21/CD35 in B cell activation. Semin Immunol 1998; 10: 279-286.
33. Gatto D, Pfister T, Jegerlehner A, Martin SW, Kopf M, Bachmann MF. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005; 201: 993-1005.
34. Soulika AM, Holland MC, Sfyroera G, Sahu A, Lambris JD. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Mol Immunol 2006; 43: 2023-2029.
35. Pappworth IY, Hayes C, Dimmick J, Morgan BP, Holers VM, Marchbank KJ. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology 2012; 217: 147-157.
36. Yechouron A, Lefebvre J, Robson HG, Rose DL, Tully JG. Fatal septicemia due to Mycoplasma arginini: a new human zoonosis. Clin Infec Dis 1992; 15: 434-438.
37. Sillo P, Pinter D, Ostorhazi E, Mazan M, Wikonkal N, Ponyai K. Eosinophilic Fasciitis associated with Mycoplasma arginini infection. J Clin Microbiol 2011; 50: 1113-1117.
38. Watanabe M, Hitomi S, Goto M, Hasegawa Y. Bloodstream infection due to Mycoplasma arginini in an immunocompromised patient. J Clin Microbiol 2012; 50: 3133-3135.
39. Song SU, Kim CS, Yoon SP, Kim SK, Lee MH, Kang JS et al. Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem Cells Dev 2008; 17: 451-461.